Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuto Shimizu

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Cancer Science|November 18, 2022
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancerMakito Miyake, Yuki Oda, Takuya Owari, et al.
Scientific Reports|October 4, 2024
Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitorsMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 23, 2022
The novel sustained 3-hydroxybutyrate donor poly-D-3-hydroxybutyric acid prevents inflammatory bowel disease through upregulation of regulatory T-cellsRimina Suzuki, Mayuko Mishima, Masaki Nagane, et al.
Hinyokika Kiyo. Acta Urologica Japonica|July 6, 2025
[Primary Malignant Melanoma Arising from the Anterior Urethra ; A Case Report]Ryotaro Kawashima, Makito Miyake, Takuto Shimizu, et al.
Exploration of Targeted Anti-Tumor Therapy|July 8, 2026
Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancerMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Asian Journal of Endoscopic Surgery|February 16, 2025
Comparison of Post-Radical Cystectomy Renal Function and Ileal Conduit-Related Complications Between Extracorporeal and Robot-Assisted Intracorporeal Urinary Diversion: A Single-Center ExperienceMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
International Urology and Nephrology|November 1, 2023
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancerMakito Miyake, Nobutaka Nishimura, Yuichi Nishioka, et al.
The FEBS Journal|April 26, 2023
Ganglioside GM3 deficiency enhances mast cell sensitivityMariko Komuro, Hinano Mizugaki, Masaki Nagane, et al.
Cancers|February 24, 2024
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint InhibitorsTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 24, 2025
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinomaNobutaka Nishimura, Makito Miyake, Norimi Takamatsu, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Cancer Science|November 18, 2022
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancerMakito Miyake, Yuki Oda, Takuya Owari, et al.
Scientific Reports|October 4, 2024
Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitorsMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 23, 2022
The novel sustained 3-hydroxybutyrate donor poly-D-3-hydroxybutyric acid prevents inflammatory bowel disease through upregulation of regulatory T-cellsRimina Suzuki, Mayuko Mishima, Masaki Nagane, et al.
Hinyokika Kiyo. Acta Urologica Japonica|July 6, 2025
[Primary Malignant Melanoma Arising from the Anterior Urethra ; A Case Report]Ryotaro Kawashima, Makito Miyake, Takuto Shimizu, et al.
Exploration of Targeted Anti-Tumor Therapy|July 8, 2026
Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancerMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Asian Journal of Endoscopic Surgery|February 16, 2025
Comparison of Post-Radical Cystectomy Renal Function and Ileal Conduit-Related Complications Between Extracorporeal and Robot-Assisted Intracorporeal Urinary Diversion: A Single-Center ExperienceMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
International Urology and Nephrology|November 1, 2023
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancerMakito Miyake, Nobutaka Nishimura, Yuichi Nishioka, et al.
The FEBS Journal|April 26, 2023
Ganglioside GM3 deficiency enhances mast cell sensitivityMariko Komuro, Hinano Mizugaki, Masaki Nagane, et al.
Cancers|February 24, 2024
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint InhibitorsTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 24, 2025
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinomaNobutaka Nishimura, Makito Miyake, Norimi Takamatsu, et al.
Pageof 8